30299-08-2

Basic information

• Product Name: Clinofibrate
• Synonyms: CLINOFIBRATE;CLINOFIBRATE(FORR&DONLY);1,1-Bis[4'-(1''-carboxy-1''-methylpropoxy)phenyl]cyclohexane;Butanoic acid, 2,2'-[cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methyl-;S 8527;2,2'-[(1,1-Cyclohexanediyl)bis(4,1-phenyleneoxy)]bis(2-methylbutanoic acid);2,2'-[Cyclohexylidenebis(4,1-phenyleneoxy)]bis(2-methylbutyric acid);2,2'-(cyclohexyliden...
• CAS NO: 30299-08-2
• Molecular Formula: C₂₈H₃₆O₆
• Molecular Weight: 468.58
• EINECS: 1312995-182-4
• Product Categories: API;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors
• Mol File: 30299-08-2.mol

Chemical Properties

• Melting Point: 143-145°C
• Boiling Point: 498.6°C (rough estimate)
• Flash Point: 200.3 °C
• Appearance: White crystalline powder
• Density: 1.1005 (rough estimate)
• Vapor Pressure: 6.38E-16mmHg at 25°C
• Refractive Index: 1.4482 (estimate)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Sligthly)
• PKA: 3.00±0.10(Predicted)
• Merck: 14,2357
• CAS DataBase Reference: Clinofibrate(CAS DataBase Reference)
• NIST Chemistry Reference: Clinofibrate(30299-08-2)
• EPA Substance Registry System: Clinofibrate(30299-08-2)

Safety Data

• RTECS: ES8900000
• Hazardous Substances Data: 30299-08-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Clinofibrate is used as an anti-atherosclerosis agent for its ability to lower lipid levels in the blood. This application is particularly important in the treatment and prevention of cardiovascular diseases, as high lipid levels are a significant risk factor for atherosclerosis and related conditions.
Clinofibrate is used as an antilipemic agent for reducing the levels of LDL and VLDL in the blood, which helps in the prevention and management of atherosclerosis and its associated health risks.

Originator

Lipocrin,Sumitomo,Japan,1981

Manufacturing Process

Into a mixture of 6.0 g of a bishydroxyphenyl derivative, and 44.0 g of methyl ethyl ketone was added 16.2 g of crushed potassium hydroxide or sodium hydroxide. Chloroform was added dropwise into the above mixture with stirring at 20°C to 80°C, and the resultant mixture was heated for 20 hours under reflux to complete the reaction. Thereafter the reaction mixture was concentrated to give a residue. Into the residue was added water. After cooling, the resultant mixture was treated with activated charcoal and acidified by diluted hydrochloric acid or sulfuric acid to give an oily substance. The oily substance was extracted by ether and the ether solution was contacted with aqueous diluted Na2CO3 solution. The separated aqueous layer was washed with ether, acidified and again extracted with ether. The obtained ester layer was dried over anhydrous sodium sulfate and concentrated to give 1.0 g of a crude product which was purified by recrystallization or chromatography, to give crystals MP 143°C to 146°C (decomp.)

InChI:InChI=1/C28H36O6/c1-5-26(3,24(29)30)33-22-14-10-20(11-15-22)28(18-8-7-9-19-28)21-12-16-23(17-13-21)34-27(4,6-2)25(31)32/h10-17H,5-9,18-19H2,1-4H3,(H,29,30)(H,31,32)

Upstream product

• 116-53-0 2-Methylbutanoic acid 
• 108-95-2 phenol 
• 108-94-1 cyclohexanone 
• 30299-28-6 2-(4-{1-[4-(1-Ethoxycarbonyl-1-methyl-propoxy)-phenyl]-cyclohexyl}-phenoxy)-2-methyl-butyric acid ethyl ester 

Downstream Products

• 1416548-79-2 C₃₆H₄₃NO₇ 
• 1416548-80-5 C₄₄H₅₀N₂O₈ 

Relevant articles and documents

Method for preparing high-purity kerley Bette

The invention relates to a preparation method of high-purity clinofibrate, the field of preparation of pharmaceutical compounds. The preparation method comprises the following steps: reacting cyclohexanone and phenol in concentrated hydrochloric acid and glacial acetic acid in a volume ratio of 3:1-7:1 to obtain an intermediate I crude product, decolorizing with a single solvent, and cooling to crystallize to obtain an intermediate I; reacting 2-methylbutyric acid with liquid bromine in phosphorus trichloride, reacting with anhydrous alcohol, extracting, and carrying out vacuum distillation to obtain an intermediate II; reacting the intermediate I and the intermediate II under solventless conditions to obtain an intermediate III; and hydrolyzing the intermediate III and sodium hydroxide, extracting, crystallizing to obtain a clinofibrate crude product; and recrystallizing with an anhydrous solvent to obtain the clinofibrate. The material proportion is adjusted to shorten the production operation period; the invention has the advantages of low energy consumption and low solvent consumption; and the obtained product has the advantages of uniform crystal grains, high purity and low cost.

Labelling of a new hypolipaemic agent with carbon 14, preparation of 1,1 bis[4 (1 carboxy 1 methylpropoxy)phenyl]cyclohexane 2 14C

1,1 Bis[4 (1 carboxy 1 methylpropoxy)phenyl] cyclohexane (S 8527) (I), a new hypolipemic agent, was labelled as C 2 with carbon 14 for the use of metabolic studies. Cyclohexane 2 14C which was prepared from potassium cyanide 14C was condensed with phenol to produce 1,1 bis(4 hydroxyphenyl)cyclohexane 2 14C (VI). Condensation of VI with ethyl methyl ketone and chloroform under a strong base (potassium hydroxide) gave S 8527 2 14C (I). A total of 3.11 mCi of pure S 8527 2 14C (I) was obtained, representing a 12% radiochemical yield from potassium cyanide 14C. Furthermore, a new radioactive by product was isolated and elucidated its structure as X.